8-K current report · filed Oct 14, 2026

Liquidia Corp (LQDA) 8-K Current Report: October 14, 2026

Item 1.02Item 7.01Item 8.01Item EX-99.1Item 1.01LQDA overview

Short answer

Liquidia Corp (LQDA) filed an 8-K current report with the SEC on October 14, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item 1.01 (Entry into a Material Definitive Agreement). Continued YUTREPIA marketing, but PH-ILD indication and promotion permanently removed, narrowing the product’s addressable market.

Liquidia Corp 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • Continued YUTREPIA marketing, but PH-ILD indication and promotion permanently removed, narrowing the product’s addressable market
  • $320.4M total UTC payments, including $175.0M within 30 business days and $145.4M in installments by January 31 and April 30, 2027
  • Additional settlement obligations: $21.75M to Sandoz, $19.05M to Henderson and $19.45M to PBM, totaling $380.65M
  • Litigation dismissals and releases conditional on payments and FDA approval removing PH-ILD from YUTREPIA labeling
  • HCR consent increased minimum cash covenant from $15.0M to $45.0M, intensifying liquidity requirements

Item 1.02 · Termination of a Material Definitive Agreement

  • Three legacy agreements terminate only after settlement payments are made, creating execution risk before Liquidia gains full contractual release
  • Promotion Agreement ends for RareGen Litigation proceeds after the Sandoz payment, preserving certain third-quarter 2026 payment obligations
  • Henderson’s $10.0 million litigation financing terminates upon full repayment, eliminating its liens and priority rights over litigation proceeds
  • PBM’s litigation-control and indemnification rights terminate upon payment, potentially restoring Liquidia PAH’s economic exposure to RareGen Litigation
  • Settlement payments restructure claims on litigation proceeds, materially affecting Liquidia’s potential recovery and remaining obligations

Item 7.01 · Regulation FD Disclosure

  • Cash and equivalents of $396.1 million as of September 30, 2026, supporting near-term operations and development funding
  • Settlement-related payments, Sandoz agreements and Treprostinil Injection rights transfer could materially alter cash flows
  • PH-ILD label removal and promotion cessation risk to YUTREPIA revenue, while PAH availability continues
  • Pipeline focus remains L606 and YUTREPIA opportunities in SSc-RP, PH-COPD and other indications
  • Preliminary unaudited September 30, 2026 financial information remains subject to accounting adjustments and review

Item 8.01 · Other Events

  • Liquidia settled all ongoing litigation with UTC, eliminating a major legal overhang
  • Concurrent Sandoz, Henderson and PBM agreements address antitrust and breach-of-contract claims tied to RareGen Litigation
  • Settlement structure links multiple agreements, potentially affecting Liquidia’s commercial and litigation obligations
  • Exhibit 99.1 contains the substantive settlement terms and investor-relevant details

Item EX-99.1 · Exhibit EX-99.1

  • Global settlement ends all six lawsuits with United Therapeutics, removing litigation overhang and securing uninterrupted PAH commercialization
  • $380.7M net payments across 2026 and 2027, including $175M within 30 business days and $145.4M in two installments
  • PH-ILD indication removed from YUTREPIA labeling after Liquidia accepted the ’327 patent ruling and waived appeal
  • Q3’26 preliminary YUTREPIA sales reached $222.7M, supporting $396.1M cash and equivalents at September 30, 2026
  • Treprostinil Injection promotional agreement terminated, ending Liquidia’s commercial support for that product

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Liquidia Corp 8-K filings

Get the next LQDA 8-K as it lands

Follow LQDA for push alerts, or ask the research agent what this filing means.